MedTrace Logo

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

NCT03799094 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-01-10

No results posted yet for this study

Summary

This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC patients.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Vitamin C

Participants will receive intravenous vitamin C therapy at the indicated dose.

DRUG

Tyrosine kinase inhibitor

Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.

Sponsors & Collaborators

  • Clifford Hospital, Guangzhou, China

    lead OTHER

Principal Investigators

  • Junwen Ou, PhD · Clifford Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-05
Primary Completion
2020-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03799094 on ClinicalTrials.gov